Cullinan Oncology, Inc.
NASDAQ:CGEM
Overview | Financials
Company Name | Cullinan Oncology, Inc. |
Symbol | CGEM |
Currency | USD |
Price | 11.6 |
Market Cap | 675,440,160 |
Dividend Yield | 0% |
52-week-range | 9.24 - 30.189 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nadim Ahmed |
Website | https://www.cullinanoncology.com |
An error occurred while fetching data.
About Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD